EURAZEO COMPLETES ITS INVESTMENT IN ULTRA PREMIUM DIRECT
Paris, May, 4, 2021
Eurazeo has completed its majority investment in Ultra Premium Direct,
alongside co- founders Sophie and Matthieu Wincker and Eutopia, existing
minority shareholder via Otium Consumer, which would reinvest in the
transaction via its new fund.
As a leading player in the French premium pet food market, Ultra Premium Direct
aims at democratizing premium pet food, distributing its products directly
through its own website and subscription service, at an attractive price point.
Focused on improving pet health and well-being Ultra Premium Direct develops
high protein products in collaboration with veterinarian nutritionists in its
owned industrial and R&D plant in Agen, South of France.
Eurazeo will invest 68 million euros to hold a majority stake in the company.
It will represent Eurazeo's Brands team second investment in Europe after the
acquisition of Swedish brand Axel Arigato in November 2020.
* Eurazeo is a leading global investment group, with a diversified portfolio of
EUR21.8 billion in Assets Under Management, including EUR15.0 billion from
third parties, invested in 450 companies. With its considerable private
equity, private debt and real assets expertise, Eurazeo accompanies
companies of all sizes, supporting their development through the commitment
of its nearly 300 professionals and by offering deep sector expertise, a
gateway to global markets, and a responsible and stable foothold for
transformational growth. Its solid institutional and family shareholder base,
robust financial struc ture free of structural debt, and flexible investment
horizon enable Eurazeo to support its companies over the long term.
* Eurazeo has offices in Paris, New York, Sao Paulo, Seoul, Shanghai,
Singapore, London, Luxembourg, Frankfurt, Berlin and Madrid.
* Eurazeo is listed on Euronext Paris.
ISIN: FR0000121121 - Bloomberg: RF FP - Reuters: EURA.PA
1, rue Georges Berger - 75017 Paris
HEAD OF COMMUNICATIONS
+33 (0)1 44 15 76 44
HEAD OF INVESTOR RELATIONS
+33 (0)1 44 15 16 76
+44 (0)7990 595 913